Value through Innovation31 October 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

07.01.2013

Lilly reassumes sole worldwide development and commercialization rights for novel basal insulin analog

11.12.2012

Boehringer Ingelheim receives EU approval for Metacam® for the relief of pain following dehorning in calves

11.12.2012

Boehringer Ingelheim discontinues Phase II trial in patients with artificial heart valves

- For Non-US, Non-UK & Non-Canadian Media Only
10.12.2012

Boehringer Ingelheim to initiate Phase III study in leukaemia with its compound volasertib* based on positive Phase II results

- For NON-US media only
10.12.2012

Treatment with Pradaxa® associated with better patient outcomes after a major bleeding event compared to warfarin

- For Non-US, Non-UK & Non-Canadian Media Only
05.12.2012

Boehringer Ingelheim and Apexigen sign manufacturing agreement for process development and early stage clinical supply

05.12.2012

New Pradaxa® safety and efficacy data to be featured at ‘Best of ASH’ session

- For Non-US, Non-UK & Non-Canadian Media Only
14.11.2012

Run for diabetes: Boehringer Ingelheim supports ‘Life for a Child’ programme on World Diabetes Day

13.11.2012

Boehringer Ingelheim and BaroFold Announce Strategic Agreement on PreEMT™ High Pressure Protein Refolding Technology

12.11.2012

Boehringer Ingelheim enters strategic collaboration agreement to support Molecular Partner’s proprietary pipeline with clinical supply of DARPin® molecules

10.11.2012

Boehringer Ingelheim’s interferon-free all-oral hepatitis C treatment+ shows up to 85% viral cure in Phase IIb study including patients with advanced liver disease

- For media outside of the U.S.A., U.K. and Canada only
08.11.2012

Recruitment complete for Trajenta® (linagliptin) cardiovascular outcome study in patients with Type 2 Diabetes

- For Non-U.S. and Non-U.K. Media
08.11.2012

RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of Pradaxa® for stroke prevention in AF

- For Non-US, Non-UK & Non-Canadian Media Only
06.11.2012

Safety and efficacy of Pradaxa® (dabigatran etexilate) reconfirmed in clinical setting for VTE prevention after total knee or hip replacement

05.11.2012

Pradaxa® - Development of antidote may expand range of methods to reverse anticoagulant effect during emergency situations

- For Non-US, Non-UK & Non-Canadian Media Only
05.11.2012

FDA and EMA reaffirm important health benefits and safety of Pradaxa® (dabigatran etexilate) for patients with atrial fibrillation

- For Non-US, Non-UK & Non-Canadian Media Only
31.10.2012

Wealth of worldwide evidence on Pradaxa® including first clinical data on long-term efficacy and safety of a novel oral anticoagulant to be presented at AHA Scientific Sessions

- For Non-US, Non-UK & Non-Canadian Media Only
31.10.2012

Boehringer Ingelheim presents robust pipeline highlighting its Respiratory R&D